Get the Stockscreener App
7.34
0.41%
-0.03
Vir Biotechnology Inc stock is traded at $7.34, with a volume of 2.84M.
It is down -0.41% in the last 24 hours and up +8.90% over the past month.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.
See More
Previous Close:
$7.37
Open:
$7.34
24h Volume:
2.84M
Relative Volume:
2.32
Market Cap:
$1.01B
Revenue:
$62.04M
Net Income/Loss:
$-533.34M
P/E Ratio:
-1.6347
EPS:
-4.49
Net Cash Flow:
$-473.07M
1W Performance:
-1.48%
1M Performance:
+8.90%
6M Performance:
-17.99%
1Y Performance:
-23.62%
1-Day Range:
$7.23
$7.56
1-Week Range:
$7.025
$7.83
52-Week Range:
$6.56
$13.09
Vir Biotechnology Inc Stock (VIR) Company Profile
Name
Vir Biotechnology Inc
Sector
Industry
Phone
415-906-4324
Address
1800 OWENS STREET, SAN FRANCISCO, CA
Compare VIR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VIR
Vir Biotechnology Inc
|
7.34 | 1.01B | 62.04M | -533.34M | -473.07M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-29-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-08-23 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-06-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Feb-21-23 | Upgrade | Goldman | Neutral → Buy |
| Jan-27-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Sep-14-22 | Initiated | SVB Leerink | Outperform |
| Sep-09-22 | Initiated | Morgan Stanley | Underweight |
| Mar-03-22 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Dec-21-21 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Oct-25-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Sep-22-21 | Downgrade | Goldman | Buy → Neutral |
| Jun-04-21 | Resumed | Robert W. Baird | Neutral |
| Jan-27-21 | Downgrade | JP Morgan | Neutral → Underweight |
| Jan-20-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-05-20 | Initiated | BofA Securities | Buy |
| Sep-14-20 | Upgrade | Goldman | Neutral → Buy |
| Sep-11-20 | Upgrade | JP Morgan | Underweight → Neutral |
| Aug-20-20 | Initiated | Needham | Buy |
| Mar-19-20 | Downgrade | JP Morgan | Neutral → Underweight |
| Mar-13-20 | Downgrade | Goldman | Buy → Neutral |
| Feb-27-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Feb-04-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-14-19 | Initiated | Robert W. Baird | Neutral |
| Nov-05-19 | Initiated | Barclays | Overweight |
| Nov-05-19 | Initiated | Cowen | Outperform |
| Nov-05-19 | Initiated | Goldman | Buy |
| Nov-05-19 | Initiated | JP Morgan | Overweight |
View All
Vir Biotechnology Inc Stock (VIR) Latest News
State Street Corp Has $42.14 Million Position in Vir Biotechnology, Inc. (NASDAQ:VIR) - MarketBeat
Y Intercept Hong Kong Ltd Reduces Holdings in Vir Biotechnology, Inc. (NASDAQ:VIR) - MarketBeat
Vir Biotechnology CEO to Present at J.P. Morgan Healthcare Conference 2024 - StockTitan
Vir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Business Wire
Long Term Trading Analysis for (VIR) - Stock Traders Daily
Vir Biotechnology's SWOT analysis: stock poised for growth amid hepatitis breakthroughs - Investing.com
GlaxoSmithKline & Vir Biotechnology's Sotrovimab Antibody Cleared for Emergency Use in the U.S. - Oficjalny Portal Gminy Brzesko
Vir Biotechnology Could Be An Early Riser In 2025 With Oncology Data In January (VIR) - Seeking Alpha
Vir Biotechnology's drugs receive FDA and EMA nods - Investing.com India
Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta - BioSpace
Vir's Hepatitis Delta Treatment Earns FDA Breakthrough & EMA PRIME Status After Strong Trial Data - StockTitan
Vir Biotechnology, Inc. (NASDAQ:VIR) Shares Acquired by Charles Schwab Investment Management Inc. - MarketBeat
(VIR) Trading Signals - Stock Traders Daily
Vir Biotechnology EVP vanina de Verneuil sells $624 in stock By Investing.com - Investing.com Canada
Vir Biotechnology EVP vanina de Verneuil sells $624 in stock - Investing.com
Vir Biotechnology (VIR) Trades Higher in Sympathy with Janux Therapeutics (JANX) - StreetInsider.com
Vir Biotechnology (NASDAQ:VIR) three-year losses have grown faster than shareholder returns have fallen, but the stock surges 12% this past week - Simply Wall St
Will Vir Biotechnology (NASDAQ:VIR) Spend Its Cash Wisely? - Yahoo Finance
Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN™ Masked T-Cell Engager Programs - BioSpace
Vir Biotechnology's SWOT analysis: stock poised for growth amid clinical progress - Investing.com
Vir Biotechnology to Participate in the 7th Annual Evercore ISI HealthCONx Conference - BioSpace
Vir Biotechnology CEO to Present at Evercore ISI HealthCONx Conference | VIR Stock News - StockTitan
Leerink Partnrs Has Pessimistic View of VIR FY2026 Earnings - MarketBeat
HC Wainwright Has Optimistic Outlook of VIR FY2024 Earnings - MarketBeat
Needham & Company LLC Reiterates Buy Rating for Vir Biotechnology (NASDAQ:VIR) - MarketBeat
Vir Biotechnology poised for outperformance, keeps buy rating on pipeline potential - Investing.com UK
Empowered Funds LLC Sells 163,723 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR) - MarketBeat
500: Something went wrong - Investing.com India
Vir Biotechnology holds a virtual investor update - Nasdaq
Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency - BioSpace
Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program - BioSpace
VIRVir Biotechnology, Inc. Latest Stock News & Market Updates - StockTitan
Vir's Hepatitis Delta Drug Achieves 100% Response Rate in Phase 2 Trial | VIR Stock News - StockTitan
EMA grants orphan drug status to Vir Biotech hepatitis treatments - Investing.com
EMA grants orphan drug status to Vir Biotech hepatitis treatments By Investing.com - Investing.com Canada
Vir Biotechnology (VIR) Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency - StreetInsider.com
Vir Biotechnology stock hits 52-week low at $7.08 - Investing.com
Vir Biotechnology stock hits 52-week low at $7.08 By Investing.com - Investing.com UK
Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD the Liver Meeting - Marketscreener.com
Vir Biotechnology (NASDAQ:VIR) Shares Down 7.4%Here's Why - MarketBeat
(VIR) Proactive Strategies - Stock Traders Daily
What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday? - Yahoo Finance
Promising hepatitis B treatment data presented by Vir Biotechnology - Investing.com
Vir Biotechnology Inc. (VIR) Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations - StreetInsider.com
Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD The Liver Meeting - Business Wire
Baillie Gifford & Co. Reduces Position in Vir Biotechnology, Inc. (NASDAQ:VIR) - MarketBeat
Vir Biotechnology's EVP sells shares worth $44,453 - Investing.com India
Vir Biotechnology's EVP sells shares worth $44,453 By Investing.com - Investing.com UK
Vir Biotechnology EVP vanina de Verneuil sells $32,332 in shares - Investing.com India
Leerink Partnrs Has Negative Outlook of VIR FY2024 Earnings - MarketBeat
HC Wainwright Expects Lower Earnings for Vir Biotechnology - MarketBeat
Vir Biotechnology Inc Stock (VIR) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):